Pharmaceutical ETF Fund (159838) premium in the market, Lepu Medical Leading

In the afternoon, the Pharmaceutical ETF Fund (159838) fell 0.44, the transaction continued to premium, with a premium of 0.15%. Recently, the funds continued to inflow.Among the ingredients stocks, Lepu's medical care led the rise, rising by nearly 4%, Hyliko, Health Yuanhe rose; Fosun Pharmaceutical, Xinhecheng, and Taikang biological decline.

Lepu Medical released a 2022-year interim report, with revenue of 5.33 billion yuan (-18.2%) in the first half of the year, net profit of 1.27 billion yuan (-26.5%), and net profit of 126 billion yuan (-26.4%), and operations.The net cash flow was 1.18 billion yuan (-44.8%).

Southwest Securities stated that it is expected that Lepu Medical's net profit is 21.5, 2.45, and 2.88 billion yuan from net profit from 2022 to 2024, and EPS is 1.19, 1.36, and 1.59 yuan, respectively, corresponding to 16, 14, and 12 times, respectively.The company's innovative equipment proportion continues to increase, the strategic transformation effect has gradually emerged, and the "buy" rating is maintained.

- END -